for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Panacea Biotec Limited

PNCA.NS

Latest Trade

114.95INR

Change

0.95(+0.83%)

Volume

73,928

Today's Range

114.15

 - 

121.95

52 Week Range

112.50

 - 

215.95

As of on the National Stock Exchange of India ∙ Minimum 15 minute delay

Pricing

Previous Close
114.00
Open
117.00
Volume
73,928
3M AVG Volume
0.63
Today's High
121.95
Today's Low
114.15
52 Week High
215.95
52 Week Low
112.50
Shares Out (MIL)
61.30
Market Cap (MIL)
6,979.52
Forward P/E
--
Dividend (Yield %)
--

Next Event

Q3 2020 Panacea Biotec Ltd Earnings Release

Latest Developments

More

India's Panacea Biotec Sept-Qtr Consol Net Loss After Tax Widens

India's Panacea Biotec June-Qtr Consol Net Loss After Tax Narrows

Panacea Biotec Gets Azacitidine USFDA Approval For U.S. Market

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Panacea Biotec Limited

Panacea Biotec Limited is a health management company. The Company's principal business activity is the manufacture of allopathic pharmaceuticals preparations. The Company's segments include Vaccines, Formulations, Research and Development; Healthcare and Real estate activities. Its Vaccines, Formulations and Research & Development segments are engaged in the business of research, development, manufacture and marketing of vaccines and branded pharmaceutical formulations. It has products for various segments, which include pediatric vaccines, pain management, diabetes management and organ transplantation. Its Healthcare segment is engaged in business of operating and maintaining hospitals. Its Real estate activities segment is engaged in the business of acquisition, construction and development of housing and commercial real estate projects. The Company's product portfolio includes prescription products in therapeutic areas, such as oncology, and nephrology and transplant management.

Industry

Biotechnology & Drugs

Contact Info

B-1 Extn / G-3

Mathura Road, Mohan Co-opIndlEstate

+91.11.41679000

https://www.panacea-biotec.com/

Executive Leadership

Soshil Kumar Jain

Whole-Time Chairman of the Board

Devender Gupta

Chief Financial Officer

Vinod Goel

Compliance Officer, Company Secretary, General Manager - Legal

Rajesh Jain

Managing Director, Executive Director

Sandeep Jain

Joint Managing Director, Executive Director

Key Stats

Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
2.43
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
278.21
LT Debt To Equity (MRQ)
227.97
Return on Investment (TTM)
--
Return on Equity (TTM)
--

Latest News

Latest News

BRIEF-India's Panacea Biotec Gets EIR From U.S. FDA For Malpur Facility

* GETS ESTABLISHMENT INSPECTION REPORT INDICATING FORMAL CLOSURE OF INSPECTION AT PHARMACEUTICAL FORMULATION FACILITY AT MALPUR

BRIEF-India's Panacea Biotec MD Ravinder Jain Passes Away

* MD RAVINDER JAIN PASSES AWAY Source text - http://bit.ly/2sLxQk2 Further company coverage:

BRIEF-India's Panacea Biotec Dec Qtr Loss Narrows

* DEC QUARTER NET LOSS 97.1 MILLION RUPEES VERSUS LOSS 254.2 MILLION RUPEES YEAR AGO

BRIEF-Panacea Biotec Signs Agreements With Serum Institute Of India And Bilthovan Biologicals B V

* SAYS SIGNED TWO LONG AGREEMENTS WITH SERUM INSTITUTE OF INDIA AND BILTHOVAN BIOLOGICALS B V Source text: http://bit.ly/2ESdxT8 Further company coverage:

BRIEF-Panacea Biotec Says U.S. FDA Accepts Co's Marketing Application For Generic Cancer Drug

* SAYS U.S. FDA ACCEPTS CO'S ANDA FOR PACLITAXEL PROTEIN BOUND PARTICLES Source text: http://bit.ly/2BnVN02 Further company coverage:

BRIEF-India's Panacea Biotec Sept-qtr loss widens

* Sept quarter net loss 56.3 million rupees versus loss 49.5 million rupees year ago

BRIEF-Panacea Biotec enters pact with Indian govt to develop, market dengue vaccine

* Co signs deal with India's technology development board for financial assistance of 289.9 million rupees

BRIEF-India's Panacea Biotec Sept-qtr loss widens

* Sept quarter net loss 56.3 million rupees versus loss 49.5 million rupees year ago

BRIEF-Panacea Biotec gets GMP compliance certificate from state service of Ukraine on Medicines and Drug Control

* Panacea Biotec - gets certificate of GMP compliance from state service of Ukraine on Medicines and Drug Control

BRIEF-India's Panacea Biotec June-qtr loss widens

* June quarter net loss 479.9 million rupees versus loss 204.9 million rupees year ago

BRIEF-Panacea Biotec expands collaboration with Apotex to launch prasugrel in US

* Says expands collaboration with Apotex to launch prasugrel in US

BRIEF-Panacea Biotec entered into joint collaboration agreement with Bionpharma Inc

* Entered into joint collaboration for development, license, among others for 7 complex generic pharmaceutical products with Bionpharma Inc Source text for Eikon: Further company coverage:

India's Narayana Hrudayalaya to buy NewRise Healthcare

Indian healthcare services provider Narayana Hrudayalaya Ltd said it would buy NewRise Healthcare Private Ltd from Panacea Biotec Ltd for an enterprise value of 1.80 billion rupees ($27.87 million).

BRIEF-Panacea Biotec launches vaccine, Easysix, for 6 preventable diseases

* Says introduces fully liquid hexavalent combination vaccine easysixtm for six preventable diseases Source text for Eikon: Further company coverage:

BRIEF-Panacea Biotec says it has not signed any definitive agreement with Narayana Hrudayalaya

* Panacea Biotec clarifies on news item "Narayana Hrudayalaya in advanced talks to buy Panacea Biotec's Gurgaon hospital."

BRIEF-Panacea Biotec Dec qtr loss widens

* Dec quarter net loss 292.5 million rupees versus loss 173.8 million rupees year ago

BRIEF-Panacea Biotec gets ANDA approval to market generic version of rizatriptan benzoate tablet

* Panacea Biotec Ltd says ANDA approval for us market and lta & award from un agencies for supply of pentavalent vaccine (easyfive-TT)

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up